Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Showing 1 to 6 of 6 results for riluzole

  1. Guidance on the use of riluzole (Rilutek) for the treatment of motor neurone disease (TA20)

    Evidence-based recommendations on the use of riluzole (Rilutek) for treating motor neurone disease (MND).

    Technology appraisal guidance
    Published
    23 January 2001
    View recommendations

    Sections for TA20

  2. Masitinib with riluzole for treating amyotrophic lateral sclerosis ID6257

    In development [GID-TA11071] Expected publication date: TBC

    Technology appraisal guidance
    In development

  3. Masitinib with riluzole for treating amyotrophic lateral sclerosis TS ID 10728

    Awaiting development [GID-TA11071] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Riluzole oral film for treating amyotrophic lateral sclerosis TS ID 11779

      Status ...

    Technology appraisal guidance
    Topic selection

  5. Motor neurone disease: assessment and management (NG42)

    This guideline covers assessing and managing motor neurone disease (MND). It aims to improve care from the time of diagnosis, and covers information and support, organisation of care, managing symptoms and preparing for end of life care.

    NICE guideline
    Last updated
    23 July 2019
    View recommendations

    Sections for NG42

  6. Past appeals and decisions

    Sézary syndrome [ID1405] 11 May 2021 TA020 Motor neurone disease - riluzole 4 January 2001 TA129 Multiple myeloma - Bortezomib 8 February